Detalhe da pesquisa
1.
Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study.
Exp Dermatol
; 32(8): 1279-1283, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37140190
2.
Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics.
J Eur Acad Dermatol Venereol
; 37(9): 1871-1880, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37247226
3.
Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events.
J Eur Acad Dermatol Venereol
; 37(5): 976-983, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652273
4.
Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial.
Br J Dermatol
; 186(1): 30-39, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33991341
5.
Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG.
J Eur Acad Dermatol Venereol
; 36(1): 60-67, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34543474
6.
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).
Br J Dermatol
; 184(4): 652-662, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32652544
7.
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
Br J Dermatol
; 185(2): 323-334, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33544883
8.
Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study.
Br J Dermatol
; 185(6): 1160-1168, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33837519
9.
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.
Br J Dermatol
; 184(5): 857-870, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32969489
10.
Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis.
J Eur Acad Dermatol Venereol
; 35 Suppl 1: 35-41, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33619776
11.
Patients with bullous pemphigoid and comorbid psoriasis present with less blisters and lower serum levels of anti-BP180 autoantibodies.
J Eur Acad Dermatol Venereol
; 35(4): 981-987, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33098720
12.
Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial.
J Eur Acad Dermatol Venereol
; 35(8): 1686-1691, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33428281
13.
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials.
J Eur Acad Dermatol Venereol
; 35(2): 476-485, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32926462
14.
[Quality of care for patients with atopic dermatitis in Germany-no improvements in indicators after ten years]. / Qualität der dermatologischen Versorgung von Neurodermitis in Deutschland keine Verbesserung der Indikatoren nach 10 Jahren.
Hautarzt
; 72(12): 1079-1089, 2021 Dec.
Artigo
em Alemão
| MEDLINE | ID: mdl-34542647
15.
A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment.
Br J Dermatol
; 182(4): 869-879, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31376153
16.
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
Br J Dermatol
; 182(3): 605-617, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31218661
17.
Continued treatment with secukinumab is associated with high retention or regain of response.
Br J Dermatol
; 182(1): 67-75, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30972746
18.
Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).
Br J Dermatol
; 183(2): 265-275, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31705526
19.
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
Br J Dermatol
; 182(1): 85-96, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31595499
20.
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies.
J Eur Acad Dermatol Venereol
; 34(12): 2809-2820, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32271970